The Indian Journal of Chest Diseases and Allied Sciences

Register      Login

VOLUME 65 , ISSUE 4 ( October-December, 2023 ) > List of Articles

LETTER TO THE EDITOR

Management Guidelines of CTD-ILD; What is New?

Yash Kedia

Keywords : Connective tissue diseases, Guidelines, Interstitial lung disease

Citation Information : Kedia Y. Management Guidelines of CTD-ILD; What is New?. Indian J Chest Dis Allied Sci 2023; 65 (4):173-175.

DOI: 10.5005/jp-journals-11007-0094

License: CC BY-NC 4.0

Published Online: 26-03-2024

Copyright Statement:  Copyright © 2023; The Author(s).


Abstract

PDF Share
  1. American College of Rheumatology. Interstitial lung disease clinical practice guidelines. Available from: https://rheumatology.org/interstitial-lung-disease-guideline#2023-ild-guideline.
  2. Hoffmann-Vold AM, Maher TM, Philpot EE, et al. The identification and management of interstitial lung disease in systemic sclerosis: Evidence-based European consensus statements. Lancet Rheumatol 2020;2(2):e71–e83. DOI: 10.1016/S2665-9913(19)30144-4.
  3. Jaeger VK, Wirz EG, Allanore Y, et al. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: A longitudinal EUSTAR study. PLoS One 2016;11(10):e0163894. DOI: 10.1371/journal.pone.0163894.
  4. Steen V, Domsic RT, Lucas M, et al. A clinical and serologic comparison of African-American and caucasian patients with systemic sclerosis. Arthritis Rheum 2012;64(9):2986–2994. DOI: 10.1002/art.34482.
  5. Goh NS, Hoyles RK, Denton CP, et al. Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol 2017;69(8):1670–1678. DOI: 10.1002/art.40130.
  6. Yasuoka H. Recent treatments of interstitial lung disease with systemic sclerosis. Clin Med Insights Circ Respir Pulm Med 2016;9(Suppl 1):97–110. DOI: 10.4137/CCRPM.S23315.
  7. Steen VD, Medsger TA. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998;41(9):1613–1619. DOI: 10.1002/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O.
  8. Naidu GSRSNK, Sharma SK, Adarsh MB, et al. Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: A double-blind, placebo-controlled, randomized trial. Rheumatol Int 2020;40(2):207–216. DOI: 10.1007/s00296-019-04481-8.
  9. Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease: Scleroderma lung study II (SLS-II), a double-blind, parallel group, randomised controlled trial. Lancet Respir Med 2016;4(9):708–719. DOI: 10.1016/S2213-2600(16)30152-7.
  10. Roofeh D, Khanna D. Management of systemic sclerosis: The first five years. Curr Opin Rheumatol 2020;32(3):228–237. DOI: 10.1097/BOR.0000000000000711.
  11. Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997;40(12):2187–2198. DOI: 10.1002/art.1780401213.
  12. Khanna D, Lin CJF, Furst DE, et al. Tocilizumab in systemic sclerosis: A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 2020;8(10):963–974. DOI: 10.1016/S2213-2600(20) 30318-0.
  13. Khanna D, Lin CJF, Furst DE, et al. Long-term safety and efficacy of tocilizumab in early systemic sclerosis-interstitial lung disease: Open-label extension of a phase 3 randomized controlled trial. Am J Respir Crit Care Med 2022;205(6):674–684. DOI: 10.1164/rccm.202103-0714OC.
  14. Otsuji N, Sugiyama K, Arifuku H, et al. Effect of tocilizumab on interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA). European Respiratory Journal 2020;56(suppl 64):747. Available from: https://erj.ersjournals.com/content/56/suppl_64/747.
  15. Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis–associated interstitial lung disease. N Engl J Med 2019;380(26):2518–2528. DOI: 10.1056/NEJMoa1903076.
  16. Kurasawa K, Arai S, Namiki Y, et al. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology (Oxford) 2018;57(12):2114–2119. DOI: 10.1093/rheumatology/key188.
  17. Li L, Li M, Li Y, Wang K, Xu S. Combination therapy of tacrolimus, high doses of glucocorticosteroids, and cyclophosphamide against existing historical treatment for patients in severe conditions of interstitial lung diseases complicated with dermatomyositis. Medicine (Baltimore) 2022;101(24):e29108. DOI: 10.1097/MD.0000000000029108.
  18. Ahmed S, Handa R. Management of connective tissue disease–related interstitial lung disease. Curr Pulmonol Rep 2022;11(3):86–98. DOI: 10.1007/s13665-022-00290-w.
  19. Solomon JJ, Danoff SK, Woodhead FA, et al. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: A randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respir Med 2023;11(1): 87–96. DOI: 10.1016/S2213-2600(22)00260-0.
  20. Spierings J, Chiu YH, Voortman M, Et al. Autologous stem-cell transplantation in systemic sclerosis-associated interstitial lung disease: Early action in selected patients rather than escalation therapy for all. Ther Adv Musculoskelet Dis 2021;13:1759720X211035196. DOI: 10.1177/1759720X211035196.
  21. Rajagopala S, Jindal A. Lung transplantation in connective tissue disease associated interstitial lung disease. Indian Journal of Rheumatology 2021;16(Suppl 1):S101–S108. DOI: 10.4103/0973-3698.332984.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.